Prophylaxis in hemophilia
Clin. biomed. res
;
43(1): 58-68, 2023.
Article
Dans Anglais
| LILACS
| ID: biblio-1435960
ABSTRACT
Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B). Prophylaxis the regular administration of therapeutic products to maintain hemostasis and prevent bleeding is the mainstream of treatment. Addressing the development and scientific evidence for administrating prophylaxis is the goal of this review. Prophylaxis is the therapeutic modality of choice for people with severe hemophilia, being considered, in principle, a lifelong treatment. It should have an early onset, ideally as a primary, or at least secondary. Even lifelong tertiary prophylaxis seems to offer benefit, although further studies are still lacking. Individualized strategies should lead to an optimization of the dilemma between better joint outcomes versus involved costs.
Sujets)
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Facteur VIII
/
Hémophilie B
/
Hémophilie A
Limites du sujet:
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Clin. biomed. res
Thème du journal:
Médicament
Année:
2023
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Hospital de Clínicas de Porto Alegre/BR
/
Universidade Estadual do Rio Grande do Sul/BR
/
Universidade Federal do Rio Grande do Sul/BR
/
Universidade de Caxias do Sul/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS